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Abstract
Purpose Since several large trials have proven the effec-
tiveness of implantable cardioverter-defibrillators (ICDs) in
patients with left ventricular dysfunction, disadvantages
have become more apparent. As the prognosis of patients
with cardiovascular diseases is improving, assessment of
ICD patients and re-evaluation of the current guidelines is
mandatory. We aimed to evaluate differences in mortality
and occurrence of (in)appropriate shocks in ICD patients
with coronary artery disease (CAD) or dilated cardiomyop-
athy (DCM).
Methods In a large teaching hospital, all consecutive patients
with systolic dysfunction due to CAD or DCM who received
an ICD with and without resynchronisation therapy, were
collected in a database.
Results A total of 320 consecutive patients (age 67±
10 years) were classified as CAD patients and 178 (63±
11 years) as DCM patients. Median follow-up was
40 months (interquartile range [IQR] 23─57 months).
All–cause mortality was 14 % (CAD 15 % vs DCM
13 %). Appropriate shocks occurred in 13 % of all patients
(CAD 15 % vs DCM 11 %, p=0.12) and inappropriate
shocks occurred in 10 % (CAD 8 % vs DCM 12 %, p=
0.27). Multivariate analysis demonstrated impaired left ven-
tricular ejection fraction, QRS >120, age ≥75 years and low
estimated glomerular filtration rate as predictors for all-
cause mortality. Predictors for inappropriate shocks were
permanent and paroxysmal atrial fibrillation.
Conclusion Mortality rates were similar in patients with CAD
and DCM who received an ICD. Furthermore, no differences
were found in the occurrence of appropriate and inappropriate
ICD interventions between these patient groups.
Keywords Implantable cardioverter-defibrillator . Systolic
dysfunction . Coronary artery disease . Dilated
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Introduction
An implantable cardioverter-defibrillator (ICD) improves sur-
vival in patients with impaired left ventricular function [1–4].
Despite these achievements, disadvantages, i.e. inappropriate
therapy or non-benefit [5–8], of ICDs have become more
apparent over the years and cost-effectiveness should be
optimised [9]. As the prognosis of patients suffering from
cardiovascular diseases is improving, the current guidelines
should be re-evaluated. For this purpose, follow-up data of
patients who were assigned to ICD therapy according to the
current guidelines are very helpful.
In the current guidelines for device-based therapy and
prevention of sudden cardiac death [10], the indications for
ICD therapy in patients with an impaired left ventricular
function due to dilated cardiomyopathy (DCM) and those
for patients with systolic dysfunction due to coronary artery
disease (CAD) are quite similar. Therefore, it is of interest to
compare the outcome of ICD patients with DCM to ICD
patients with CAD, to verify whether the current guidelines
are still valid.
The aim of this study was to evaluate mortality and occur-
rence of both appropriate and inappropriate ICD shocks in
patients with an impaired left ventricular function due to CAD
and DCM. Furthermore, we assessed predictors for mortality,
appropriate and inappropriate shocks.
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A database was constructed including all consecutive patients
who received an ICD between January 2005 and June 2012 in
a large teaching hospital. Follow-up lasted until October 2012.
Therapy assignment was based on the European Society of
Cardiology guidelines for device-based therapy [10]. Baseline
characteristics of all patients were collected by reviewing
hospital records and included demographics, medical history,
medication, cardiovascular risk factors and electrocardio-
graphic characteristics. Fifty-two patients who received their
ICD for other reasons than CAD or DCM (e.g. idiopathic
ventricular fibrillation, hypertrophic cardiomyopathy, arrhyth-
mogenic right ventricular cardiomyopathy, long-QT syn-
drome, Brugada syndrome, catecholaminergic polymorphic
ventricular tachycardia) were excluded. Patients were consid-
ered CAD patients if they had a history of myocardial infarc-
tion (including Q-wave or enzyme-positive), a history of CAD
at coronary angiography or one or more coronary artery
bypass grafts or percutaneous coronary interventions. Renal
function was assessed by estimating the baseline glomerular
filtration rate (eGFR) using the abbreviated Modification of
Diet in Renal Disease (MDRD) Study equation: eGFR (mL/
min/1.73 m2 of body surface area) =186× (serum creatinine in
mg/dL) −1.154×(age)−0.203×0.742 in female subjects. Re-
nal failure was defined as an eGFR <60 mL/min/1.73 m2.
ICD follow-up
The majority of devices had a three-zone configuration. The
first zone was a monitor-only zone, which was set to 160±
10 bpm, the VT zone was set to 190±12 bpm and the VF zone
was set to >209±15 bpm. In the devices fromMedtronic Inc.,
Minneapolis, MN, USA, the number of intervals to detect was
set to 18/24 episodes in all zones. In the devices from Boston
Scientific Inc., Indianapolis, IN, USA, the number of intervals
to detect was set to 8/10 intervals, with a duration of 8 s in the
VT zone and 5 s in the VF zone. For all patients, ICD
programming was intended to avoid inappropriate therapy
by activating the available discriminators, e.g. dual-chamber
algorithms, onset, stability and morphology. For each patient,
programming was tailored according to the clinical
presentation.
During in-hospital and remote ICD follow-up, as part of
usual care, ICD printouts were obtained every 3 months to
determine the number and type of arrhythmias and the number
of appropriate and inappropriate shocks. Patients were advised
to contact the hospital after experiencing ICD therapy or
required to visit the hospital if an ICD shock was detected
by remote monitoring. ICD therapy was only considered
appropriate when delivered for ventricular tachyarrhythmias.
All debatable ICD events were double-checked by multiple
experts and discussed at a weekly meeting.
Statistical analysis
Continuous data were analysed with the Student’s t test or
Mann–Whitney U test, when appropriate. Categorical character-
istics were compared by using the χ2 test. Kaplan-Meier’s log-
rank test was used to compare differences in all-cause mortality,
appropriate shocks and inappropriate shocks between CAD and
DCM patients. Furthermore, multivariable Cox proportional
hazards regression was used to examine the association between
patient characteristics and outcome (hazard ratios, HRs). Char-
acteristics were entered into the multivariable model if they
showed a statistically significant association with the outcome
during univariable analysis (P value <0.05). Overall statistical
significance was set at a 2-tailed P value <0.05. SPSS 20.0
(SPSS Inc, Chicago, IL) was used for the statistical analysis.
Results
Study population
The study population consisted of 498 consecutive patients
who received an ICD in a large teaching hospital between
January 2005 and June 2012. Baseline characteristics are
displayed in Table 1. The CAD group comprised 320 patients
(64%). The DCMgroup consisted of 178 (36%) patients. The
CAD group containedmoremales than the DCM group (CAD
85 % vs. DCM 62 %, p<0.001) and were older (CAD 67±10
vs DCM 63±11, p<0.047). Mean left ventricular ejection
fraction (LVEF) was 24 %±7 % and was not significantly
lower in one of the groups (25±6 vs 23±8, p<0.131). Perma-
nent atrial fibrillation (AF) was more frequent in DCM pa-
tients (8 % vs 18 %, p=0.002).
The use of beta-blockers (CAD 93 % vs DCM 93 %, p=
0.76) and ACE inhibitors/ARBs (CAD 96 % vs DCM 97 %,
p=0.59) did not significantly differ between the groups, but
the use of diuretics was higher in patients with DCM (CAD
74% vs DCM 84%, p=0.008). A total of 166 patients (33 %)
received cardiac resynchronisation therapy (CRT) (CAD 28%
vs DCM 43 %, p<0.001).
Mortality
Figure 1 displays the results of our outcome on mortality,
appropriate and inappropriate shocks. Overall mortality of
the total study population was 14.5 % (72 patients), during a
median follow-up of 40 months (IQR 23–57 months) with a
median survival time of 31 months (IQR 20–44 months).
There were no significant differences in mortality between
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CAD (49 patients, 15 %) and DCM (23 patients, 13 %)
patients (p=0.46) (Fig. 2).
Univariable analysis displayed the following predictors for
mortality: age ≥75 years, LVEF, New York Heart Association
(NYHA) class III-IV, permanent AF, QRS >120 ms, eGFR
and haemoglobin. Multivariate analyses showed that impaired
LVEF (HR 0.94, CI 0.90–0.99), age ≥75 years (HR 2.18, CI
1.19–3.97), QRS >120 ms (HR 2.50, CI 1.21–5.16) and low
eGFR (HR 0.98, CI 0.97–0.99) were independent predictors
for mortality.
Appropriate ICD therapy
A total of 67 patients (13.5 %) received ≥1 appropriate shocks
and 43 patients (9 %) received >1 appropriate shocks during
follow-up. The median interval to first appropriate shock after
ICD implantation was 21.8 months (IQR 4.9–35.0 months).
Cumulative incidence of appropriate shocks was 4.4, 7.2 and
13.1 % at 1, 2 and 5 years follow-up, respectively. There were
no significant differences in the occurrence of appropriate
shocks between CAD patients and DCM patients (CAD
15.0 % vs DCM 10.7 %, p=0.12) (Fig. 3a). Use of digoxin
(15 vs 4 %, HR 2.97, CI 1.50–5.88) and a history of smoking
(62 % vs 48 %, HR 2.00, CI 1.77–2.98) predicted appropriate
shocks.
Inappropriate ICD therapy
Inappropriate ICD shocks occurred in 48 patients (9.6 %).
Twenty-four patients (5 %) had >1 episode of inappropriate
shocks. The median time between implantation and the first
inappropriate shock was 6.1 months (IQR 2.3–26.6 months).
Cumulative incidence of inappropriate shock therapy was 5.4,
7.2 and 9.0 % at 1, 2 and 5 years of follow-up. There was no
Table 1 Baseline characteristics
Characteristic All (n=498) CAD (n=320) DCM (n=178) P Value
Age, years 66±10 67±10 63±11 0.047
Male gender 382(77) 272(85) 110(62) <0.001
LVEF, 24±7 25±6 23±8 0.13
NYHA classification
I–II 359(80) 233 (81) 126(79) 0.62
III–IV 87 (20) 54(19) 33(21)
History of atrial fibrillation
Permanent 59(12) 27(8) 32(18) 0.002
Paroxysmal 52(10) 39(12) 13(7) 0.09
QRS duration, ms 132±32 130±31 136±35 0.003
QRS >120 ms 254(53) 159(52) 95(57) 0.29
Serum creatinine (μmol/L) 117±79 123±90 105±51 0.06
eGFR (ml/min/1.73 m2) 65±23 63±23 68±22 0.73
Renal failure 176(40) 121(43) 55(35) 0.13
Haemoglobin (mmol/L) 8.6±1.0 8.6±1.0 8.6±1.1 0.53
Implanted device
Atrial lead 353(71) 223(70) 130(73) 0.43
CRT 166(33) 89(28) 77(43) <0.001
Risk factors
Diabetes 95(19) 69(22) 26(15) 0.06
History of smoking 213(50) 144(53) 69(45) 0.12
Hypertension 147(42) 136(44) 75(44) 0.90
Cardiovascular medication
Amiodarone 56(11) 42(13) 14(8) 0.08
Beta-blocker 457(93) 294(93) 163(93) 0.95
Digoxin 29(6) 12(4) 17(10) 0.008
ACE inhibitor/ATII antagonist 474(96) 304(96) 170(97) 0.59
Diuretics 382(77) 234(74) 148(84) 0.008
Continuous variables are expressed as mean±standard deviation. Categorical variables are expressed as count (percentage). Valid percentages may vary
for some counts, because of missing values. ACE indicates angiotensin-converting enzyme; ATII angiotensin-II; eGFR estimated glomerular filtration
rate; ICD Implantable cardioverter-defibrillator; LVEF Left ventricular ejection fraction; NYHA New York Heart Association
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significant difference in occurrence of inappropriate shock
therapy between CAD patients and DCM patients (CAD
8 % vs DCM 12 %, p=0.27) (Fig. 3b). Inappropriate shocks
occurred significantly more in patients with permanent AF (22
vs 8 %, p=0.001), and also in patients with paroxysmal AF
(17 vs 9 %, p=0.048). Most inappropriate shocks in this study
were caused by supraventricular tachyarrhythmias (78 %),
mainly AF. Other causes of inappropriate shocks were shock
lead dysfunction (18 %) and T wave oversensing (4 %).
Multivariate analyses displayed permanent AF (HR 2.85, CI
1.16-7.01) and paroxysmal AF (HR 2.84, CI 1.20–6.74) as
independent predictors for inappropriate shocks.
Discussion
We performed a retrospective, observational, follow-up study,
on 498 real-life patients, treated with an ICD and evaluated the
difference in mortality and occurrence of ICD shocks in
patients with left ventricular dysfunction due to CAD versus
DCM. All patients received their ICD according to the current
guidelines.
The major findings of this study were: (1) Mortality rates
are equal in CAD and DCM patients; (2) Incidence of
Fig. 1 All-cause mortality,
appropriate and inappropriate
shocks in coronary artery disease
(CAD) and dilated
cardiomyopathy (DCM) patients
Fig. 2 Kaplan-Meier survival curve of all-cause mortality. Coronary
artery disease (CAD) versus dilated cardiomyopathy (DCM) patients
Fig. 3 Kaplan-Meier hazard curve of a appropriate shocks and b inap-
propriate shocks. Coronary artery disease (CAD) versus dilated cardio-
myopathy (DCM) patients
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appropriate and inappropriate shocks was similar in both
groups; (3) Predictors for mortality in ICD patients were
impaired LVEF, age ≥75 years, QRS >120 ms and low eGFR;
(4) Predictors for inappropriate ICD intervention were perma-
nent and paroxysmal AF.
Mortality
Overall cumulative incidence of all-cause mortality of the total
study population was 14.5 % and at 1, 2 and 5 years, mortality
rates were 2.2, 4.2 and 13.5 %, respectively. For CAD pa-
tients, mortality rates at 1, 2 and 5 years were 2.5, 5.3 and
14.1 % respectively, and for DCM patients 1.7, 2.8 and
12.4 %. Compared with the landmark trials, the cumulative
incidence off all-cause mortality was relatively low. The Sud-
den Cardiac Death in Heart Failure Trial (SCD-HeFT) found a
total mortality rate of 29 % at 5-year follow-up and the
Multicenter Automatic Defibrillator Implantation Trial II
(MADIT-II) reported a mortality rate of 16 % at 2 years
follow-up and 52 % at 8 years [2, 3, 11]. This lower mortality
could be explained by the fact that treatment of patients with
systolic dysfunction has improved over time, which may have
contributed to a lower mortality in our study population com-
pared with the trials mentioned. Another factor contributing to
the lower mortality could be due to the fact that 33 % of our
study population received CRT, which improves left ventric-
ular function and reduces mortality [12].
As ICD implantation and follow-up is expensive and as
costs in medical practice are rising, a stricter selection of
eligible patients is mandatory. The relatively low mortality
in our study population calls for reassessment of the indica-
tions for an ICD. Therefore, further studies and registries of
real-life ICD patients are required to make a more appropriate
selection of patients eligible for ICD implantation possible.
Finally, whereas ICDs only act as a ‘safety net’ and antiar-
rhythmic medication has potential side effects and requires
close monitoring, the search for other methods to withstand
arrhythmias continues. Catheter ablation is an accepted tech-
nique and nowadays commonly used in the treatment of
arrhythmias. Catheter ablation has proven its effectiveness in
the treatment of VTs in patients with structural heart disease
due to CAD or DCM with even higher success rates in CAD
patients [13].
Appropriate intervention
In our study, 13.5% of all patients received appropriate shocks,
and this number did not significantly differ between CAD and
DCM patients. The SCD-HeFT trial reported a total number of
appropriate shocks of 21 %, which is higher than the 13 % of
all patients receiving appropriate shocks that we reported. This
difference might be clarified by the fact that device program-
ming has improved over time and antiarrhythmic medication
has been enhanced. Also, as stated before, 33 % of our study
population received CRT, which could also have had a bene-
ficial effect on the number of appropriate shocks by increasing
LVEF.
There is some evidence that the number of ventricular
tachyarrhythmias is comparable in CAD patients and DCM
patients.[14, 15] This had also been shown by some small
previous studies.[16, 17] Our study adds to these findings by
showing that the number of ICD shocks is also equivalent in
these two groups, even though one-third of our patients re-
ceived CRT, which may have a more beneficial effect on
LVEF in DCM patients compared with CAD patients.[18]
Our findings confirm the validity of the current guidelines.
Recently, studies have shown that medication indeed re-
duces appropriate ICD therapy in patients with ischaemic heart
disease [19–21]. Since ventricular tachyarrhythmias are the
major cause of sudden cardiac death, it is important to reduce
these arrhythmias and therefore appropriate shocks, which have
also proven to be an independent predictor of mortality [22].
Our study reveals that a history of smoking is a predictor
for appropriate shocks, which has been shown before in
previous studies [23]. Smokers have increased atherosclerosis,
which increases the occurrence of ischaemic events, and myo-
cardial scarring, eventually resulting in more tachyarrhyth-
mias and consequently more appropriate shocks.
Finally, most of the patients who received an ICD never
received shock therapy, suggesting that a more patient-
focused risk stratification could improve clinical benefits and
cost-effectiveness [24].
Inappropriate intervention
In this study, inappropriate shocks occurred in 9.6 % of all
patients, mostly caused by atrial tachyarrhythmias classified
as ventricular tachyarrhythmias, which subsequently caused
inappropriate discharges.
Age <75 years was also associated with inappropriate
shocks. Younger age is associated with sinus tachycardia
and abnormal sensing. This finding has been reported before
[25], and is most likely the explanation for the association
between age <75 years and inappropriate shocks. Patients who
had an ICD as secondary prevention had a slightly better
LVEF compared with the primary prevention patients and a
lower NYHA class. Possibly, these patients were more phys-
ically active, which could also lead to a higher number of
shocks from sinus tachycardia or abnormal sensing.
The most frequent causes of inappropriate therapy have
been studied, and can result in reduced quality of life and even
provocation of ventricular arrhythmias.[5, 26] An additional
phenomenon is phantom shocks - the sensation of an ICD
discharge in the absence of an actual discharge – which occur,
though not significantly, more in patients who received appro-
priate or inappropriate shocks [27]. Therefore, the occurrence
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of inappropriate shocks should be minimised as much as
possible. Recent studies have shown that enhanced program-
ming algorithms during follow-up reduces inappropriate ther-
apy and even mortality [28, 29].
Limitations
The present study has several limitations. Patients were in-
cluded in the period between January 2005 and June 2012, so
follow-up of the last included patients was only 3 months
while some patients have a follow-up of up to 7 years. Within
this period of time, multiple publications on treatment of
ventricular tachyarrhythmias and device-based therapy have
changed the selection of eligible patients for ICD treatment.
This could have caused heterogeneity in the study population,
which may have affected the outcome. This limitation did not
influence the aim of the study, since this limitation applies to
both CAD and DCM patients.
A second limitation is the fact that this study was performed
retrospectively, which makes data collection challenging. Nev-
ertheless, all data on primary and secondary outcomes could be
collected without loss to follow-up.
Conclusion
This study shows that mortality and occurrence of appropriate
and inappropriate ICD shocks are similar in patients with an
ischaemic or a dilated cardiomyopathy. An impaired LVEF,
age ≥75 years, QRS >120 ms and low eGFR predicted mor-
tality. Use of digoxin and a history of smoking predicted
appropriate shocks. Permanent AF and paroxysmal AF are
predictors for inappropriate shocks.
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